Samsung Pharmaceuticals

Samsung Pharm is a South Korean pharmaceutical company established in 1929, specializing in the development, manufacturing, and distribution of prescription drugs, over-the-counter (OTC) medicines, and health supplements. The company is well-known for its long-standing consumer products like 'Woohwang Chungsimwon' and 'Gas Myung-soo,' but has recently pivoted towards advanced biotechnology and oncology. A key focus of their current R&D is RiaVax (GV1001), a peptide-based immunotherapy targeting telomerase, which has received conditional approval in Korea for the treatment of locally advanced or metastatic pancreatic cancer. Samsung Pharm operates multiple manufacturing facilities and continues to expand its pipeline into neurodegenerative diseases and other high-need therapeutic areas through strategic partnerships.